Bio View Ltd.

Investor Presentation • Jan 5, 2023

Investor Presentation

November 2022

Legal clarification/forward-looking information

The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein

This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of the Company' s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy, the any of the Company's securities in any jurisdiction.

The Company does not undertake to update or modify the information included in this presentation to reflect events or any changes involving data editing, processing, or segmentation other than as provided herein or any amendments that may be implemented after the preparation of this presentation. Please also note that the Company's plans and strategy as outlined in this presentation apply to the date of their publication and may be changed at the decision of the Board of Directors or the Company's management, as may happen from time to time. The evaluations in this presentation were provided by the Company's management and are not necessarily the only evaluations available.

This presentation includes forecasts, estimates, indexes, and other information relating to future events and/or matters whose occurrence is uncertain and are not under the Company's control. Such details are regarded as forward-looking information, as defined in the Securities Law, 5728-1968. Such events may not happen, in whole or in part, or may happen in a manner substantially different from any forecast. This forward-looking information is based on subjective assessments and assumptions by the Company's management and is derived from facts and data regarding the Company's current business activities. These subjective assessments and assumptions are inherently uncertain, as they involve risks that result from the Company's activities and are not controlled by the Company, any of which, or a combination thereof, may negatively affect the outcomes of such Company activities. Furthermore, should any forecasts and assessments turn out to be true or should any events or developments occur that have an impact on the general environment, market conditions, or external elements that affect Company activities, these shall be regarded as events that can neither be assessed beforehand nor be controlled by the Company. This presentation includes scientific, statistical, and other data published by third parties, the contents of which have not been reviewed by the Company.

Neither this presentation nor anything in it shall form a basis of any contract or commitment. This presentation is not intended to be relied upon as advice to invest for potential investors and does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate.

2

This presentation may contain information that has been or will be presented differently in reports published by the Company for the general public. Such information may include data characterized and/or edited and/or segmented differently in the reports published by the company for the general public.

Who we are

Company Established in 2000 Specializes in a variety of disciplines – R&D, manufacturing and marketing of cell imaging and analysis systems for cancer diagnostic testing

Global Distribution Agreements •Abbott Molecular •Sanmed Bio (China)

Company's systems regulatory approvals: •FDA - USA •NMPA - China •CE IVDR - Europe •Medical Device - Israel

• KFDA - Korea

Team of 25 employees Global R&D and Service Center in Rehovot, Israel

Over 650 systems installed around the world

Annual revenue from instrument sales and service contracts of approximately 30 million NIS per year Profitable with a positive cash flow

Fully owned US subsidiary engaging in marketing, sales, and rendering service to North American clients

BioView's instruments are sold to pathology, cytogenetics, and cytology laboratories

Business collaborations with industry leading liquid biopsy test manufacturers, which integrated the company instruments with their product offering

Our Mission:

4

To become a leading company developing, marketing, and selling liquid biopsy-based medical tests to improve the treatment and monitoring of cancer patients as well as minimize any discomfort and risks of existing tests

The company's expertise and market position

• Development and manufacturing of mechanicaloptical automated systems for medical use
• Regulatory-approved cell imaging systems
• Development of advanced image-processing algorithms
• Understanding of oncology laboratories workflows
• Proven experience in system characterization and implementation for innovative liquid biopsy testing
• A global reputation for expertise in automated imaging and detection of circulating cancer cells.

Areas of activity

Selling systems for clinical use to hospitals and laboratories

Advantages • Regulatory approvals in key markets

1 2

• Global distribution system
• Global reputation and customer base
• Market characterized by frequent system replacements

Challenges • Recurring sales revenues generated through service contracts and upgrades

Selling systems to companies developing liquid biopsy tests

• Advantages BioView is at the technological forefront in the field of automated cell imaging and analysis
  • A groundbreaking and required value proposition
  • Potential for significant growth and profitability
  • Strategic partnerships and potential for recurring revenues from clinical tests
• Challenges Relying on the successful deployment of liquid biopsy test developed by commercial partners
  • Limited to the markets targeted by the commercial partner
  • Uncertainty regarding the generation of constant revenues

Cancer diagnosis Selling systems for clinical use to hospitals and private laboratories

BioView systems help standardize analysis and reporting and facilitate the expansion of laboratory services. System performance is validated by clinical studies that served as the basis of the systems FDA and CE clearances. The system can accommodate multiple applications, including analysis and clinical reporting for:

Metaphase-based Blood cancer Bladder cancer Lung cancer Breast cancer cancer analysis

System key features:

• Artificial intelligence image processing algorithms
• Digital reporting
• Remote analysis (web-based)

Selling systems for clinical use to hospitals and private laboratories

Cancer diagnosis – Some of the company's systems

Duet-3 Scan of up to 50 samples in single run

Allegro Plus Accord Plus Scan of up to 8 samples in single run

Single slide scan

SoloWeb

Remote secured analysis and reporting via web browser

Selling systems to companies developing liquid biopsy tests for future marketing

Liquid biopsy-based tests for therapeutic and patient monitoring

Traditional biopsy

• Invasive procedure

8

• Requires expert laboratory resources and time
• Tissue sampling from a single tumor area
• Does not allow frequent retesting
• Risk of secondary complications (infections)

Liquid biopsy

• Non-invasive procedure (simple blood test)
• Can be performed by the community health workers
• Blood sample represent local and metastatic tumors
• Enables frequent retesting

Selling Systems to companies interested in incorporating their liquid biopsy test

Liquid biopsy-based monitoring and therapy selection for cancer patients

DENOVO

Dedicated scanning system for imaging, detection, and characterization of cancer cells from liquid biopsy tests

9

Single-click operation

Compact design

High sample capacity

High Throughput

Selling Systems to companies interested in incorporating their liquid biopsy test

Industry leader specializing in automated liquid biopsy imaging and analysis.

The company maintains extensive collaborations with companies that develop liquid biopsy-based tests and utilize BioView imaging systems as an integral part of their clinical assay.

Lung cancer Brain cancer Breast cancer Liver cancer Head and neck cancer Detection Monitoring Therapy selection Diagnostic services for pharmaceutical companies

Future Growth Engines

Development of "sample-to-answer" liquid biopsy test platform

Market potential Advantages

• High potential for recurring revenues generated by sale of tests
• Potential distribution of test to multiple markets

• Significant potential for expansion to both clinical and pharmacological markets

• Leveraging BioView's knowledge and experience to respond to an existing unmet clinical need

  • Utilize USA subsidiary for marketing and sales
  • Existing global customer base in the pathology Industry facilitating efficient market entry

"sample-to-answer" liquid biopsy test development

Development of a liquid biopsy test includes; preparing and processing blood sample, detecting and characterizing of cancer cells - to obtain actionable clinical data for treatment of cancer patients

"sample-to-answer" liquid biopsy test development

Development of a liquid biopsy test includes; preparing and processing blood sample, detecting and characterizing of cancer cells - to obtain actionable clinical data for treatment of cancer patients

Increasing the Company's revenues

Sell test services to pharmaceutical companies for drug research and development

Selling tests to hospitals and laboratories for clinical use

Leveraging the company's liquid biopsy testing capabilities

• Proven capabilities in the field of automated circulating cancer cell 1 imaging and detection
• Relationships with leading companies for blood processing equipment for 2 liquid biopsy test
• Proven experience integrating systems with array of liquid biopsy 3 tests for clinical assay
• Pathology laboratories customer base to facilitate collaborations with global 4 leading oncology institutes

Potential markets of liquid biopsy testing

Example 1 – Head and neck cancer

~900,000 ~50,000 ~206,000

New patients are diagnosed every year globally with a projected 30% increase in 10 years

New patients are diagnosed in the USA every year

Cancer patients in USA on average per year

Cost of patient-monitoring by PET-CT Cost of patient treatment. \$4,000 - \$6,000 ~\$10,000

15-30% of patients respond to treatment

Clinical use of liquid biopsy testing

Personalized care to raise the rate of patients responding to drugs and prevent patient suffering due to 1 ineffective treatment

Monitoring patients during treatment for 2therapeutic resistance

Monitoring and early detection of cancer spread to facilitate 3alteration of treatment

270,000 90,000 Patients per year Patients per year

450,000 Patients per year

Potential market for liquid biopsy tests

Example 1 – Head and neck cancer

Distribution of new cases each year by country

15

https://gco.iarc.fr/today/online-analysis-

pie?v=2020&mode=population&mode\_population=continents&population=900&populations=900&key=total&sex= 0&cancer=14_1_3_4_2&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_gr oup%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=0&include_nmsc_other=1&half_pie=0&donut=0

Distribution of total patients around the world by regions (over 5 years period)

Total: 847,677 Total: 2,278,970

https://gco.iarc.fr/today/online-analysis-

pie?v=2020&mode=population&mode\_population=continents&population=900&populations=900&key=total&sex= 0&cancer=14_1_3_4_2&type=2&statistic=5&prevalence=1&population_group=0&ages_group%5B%5D=0&ages_gr oup%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=0&include_nmsc_other=1&half_pie=0&donut=0

Tests' market potential

16

Head and neck cancer – global market potential

	Monitoring and early detection of cancer spreading from the tumor and appropriate treatment adaptation (450,000)	Personalized treatment adaptation intended to raise the rate of patients responding to drugs and preventing patient suffering due to unnecessary and ineffective treatment (270,000)	Monitoring patients during treatment for the identification of therapeutic resistance (90,000)
	Testing cost \$ 600
Market share upon obtaining regulatory approval	Two tests per year % market penetration, Year 1: 1% % market penetration, Year 2: 2.5% % market penetration, Year 3: 5%	% market penetration, Year 1: 2% % market penetration, Year 2: 5% % market penetration, Year 3: 10%	% market penetration, Year 1: 2% % market penetration, Year 2: 5% % market penetration, Year 3: 10%
Year 1 Revenue	\$ 5.4 million	\$ 3.2 million	\$ 1.1 million
Year 1 Total Revenue	\$ 9.7 million
Year 2 Revenue	\$ 13.5 million	\$ 8.1 million	\$ 2.7 million
Year 2 Total Revenue	\$ 24.3 million
Year 3 Revenue	\$ 27 million	\$ 16.2 million	\$ 5.4 million
Year 3 Total Revenue		\$ 48.6 million

Potential market for liquid biopsy tests

Example 2 – Prostate cancer

~200,000

new patients are diagnosed in the USA every year

36% of treated patients, the cancer will return Over 2 million

people are monitored per year for cancer recurrence

biopsy testing cost ~\$2,000

\$90,000-\$250,000

the cost of treatments per patient per year. With some treatments, up to 50% of patients do not respond

Distribution of new cases each year by country

Total: 1,414,259

https://gco.iarc.fr/today/online-analysis-

pie?v=2020&mode=population&mode_population=countries&population=900& populations=900&key=total&sex=1&cancer=27&type=0&statistic=5&prevalence= 0&population\_group=0&ages\_group%5B%5D=0&ages\_group%5B%5D=17&nb\_it ems=7&group_cancer=1&include_nmsc=0&include_nmsc_other=1&half_pie=0& donut=0

Tests' potential market value

Prostate cancer – potential USA market

Clinical use of liquid biopsy testing for:

18

Test purpose	Potential indemnification by insurance companies (USD)	Number of patients per year	Number of tests per patient per year	Total market potential per year
Personalized treatment adaptation	1500	512,000	1	\$ 768 million
Post-treatment patient monitoring	500	1,995,000	1	\$ 997 million

Thank You!